
26/07/2025
【兒童糖尿協會就政府回應資助CGM事宜之回覆 │ YDA Response to Government’s Reply on CGM Subsidies 】
兒童糖尿協會對政府就林哲玄議員於立法會提出,有關為一型糖尿病患者提供持續血糖監測儀CGM資助的回應,表示深切失望。政府的回應明顯忽視一型與二型糖尿病之間的根本差異。一型糖尿病屬自身免疫系統疾病,患者必須接受密集式胰島素治療及持續血糖監測,而二型糖尿病之治療方式則有所不同,故有關醫療政策及資源分配應作清晰區分。
政府回應指,如持續向全港超過658,000名糖尿病患者提供CGM,可能對醫療人手構成壓力,每年涉及數十億港元開支。然而,該說法將所有糖尿病患者劃一處理,完全忽略一型患者在血糖上需要更頻繁管理,故CGM對他們而言屬基本所需。
若僅集中考慮CGM前期成本支出,將忽視其帶來的整體經濟效益。為一型糖尿病患者提供CGM資助,可透過改善血糖控制、減少住院次數及降低併發症,從而長遠節省醫療開支。
儘管醫管局現時根據臨床準則,為部分患者提供有限數量的CGM,然而有多項研究表明,CGM有助穩定血糖水平、減少高低血糖情況,有效預防多種併發症。透過針對性資助措施,可在不加重醫療系統負擔的情況下,讓患者受惠。
本會促請政府,落實針對性支援措施,優先保障一型糖尿病患者的健康與福祉。
詳細聲明請參閱︰https://shorturl.at/d58p2
We express deep disappointment with the Government’s reply to Hon Dr David Lam’s LegCo question on subsidies for CGMs for people with Type 1 diabetes. The response overlooks critical differences between Type 1 and Type 2 diabetes. Type 1 is an autoimmune condition requiring intensive insulin therapy and continuous glucose monitoring, while Type 2 involves different treatments. These differences demand distinct healthcare policies and resource allocation.
The Government states that providing CGMs to over 658,000 people with diabetes continuously could overwhelm healthcare personnel and cost billions annually. However, this groups all people with diabetes together and ignores that those with Type 1 require more intensive glucose management, making CGMs essential.
Focusing solely on upfront CGM costs overlooks the broader economic benefits. Subsidising CGMs for people with Type 1 diabetes can deliver long-term savings through improved glycaemic control, fewer hospital admissions, and reduced complications.
While the Hospital Authority provides a limited supply of CGMs free to some individuals under clinical criteria, CGMs are proven to improve control, reduce hypo- and hyperglycaemic episodes, and prevent complications. Targeted subsidy support can provide these benefits without overwhelming healthcare resources or costs.
We call on policymakers to prioritise the health and well-being of people with Type 1 diabetes through targeted support.
Read our full response here: https://shorturl.at/PFdML